ATS 2015 exhibitors will describe options that address the diagnosis and treatment of COPD, asthma, and other respiratory conditions.
COPD and asthma are ranked the highest by ATS International Conference attendees as their topics of interest, which is reflected in the many sessions that will be available at ATS 2015. In the ATS 2015 Exhibit Hall, attendees will learn more about options that will help them diagnose and treat these and other respiratory conditions.
In Booth 639, Boston Scientific Corporation will showcase the Alair Bronchial Thermoplasty System, the first FDA-approved non-drug therapy for adult patients with severe asthma.
Methapharm, Inc. in Booth 647 will offer two new training videos to help professionals maintain best practices in asthma diagnostics, either through training of new technicians or refreshing the more experienced individuals. The first covers “Mixing Methacholine Dilutions for Bronchoprovocation Challenge Testing,” and the second video is “Performing a Methacholine Challenge Test.”
Nonin Medical Inc. will present its white paper on active co-management of acute and chronic COPD phases in Booth 937. The company also is able to make arrangements to introduce you to industry experts and provide a sneak peek of its new COPD Patient Hospital 30-Day Readmission Reduction Program.
Learn about new product launches and treatment options during any of 19 Industry Theater and Mini Industry Theater discussions in the Exhibit Hall. Complimentary boxed lunch provided by the ATS while supplies last. (Photo: Robert Wilson/RC Photographic Productions)
Novartis Pharma AG will present an Industry Theater from 1 to 1:45 p.m. on Monday, May 18, to help attendees become up to date in the rapidly evolving COPD therapy area by exploring the latest evidence in the management of COPD, including clinical data from the most recent trials in dual bronchodilation. The program will look closely at current practice, discuss considerations related to the delivery and regimens of inhaled therapies, and present evidence on the risks and benefits of inhaled corticosteroids in COPD. Please note that due to local regulations, this program is only available to non-U.S. based physicians. Novartis Pharmaceuticals will be in Booth 745.
PneumRx, Inc., Booth 321, will host a series of Ask-the-Expert sessions with leaders in interventional pulmonology to discuss their experiences in treating patients with severe emphysema with the innovative RePneuEndobronchial Coil System. Physicians from the United States, Germany, France, and other countries will be available to answer questions about patient selection, follow-up, mechanism of action, the role of coil therapy in emphysema management, as well as proctor coil demonstrations.
Be sure to add these exhibitors your itinerary.